• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • DMF (Drug Master Filing) – Pharmaceutical Products
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • CML (China Manufacture Licence) – Pressure vessels
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Company Profile
    • Partners
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Information
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • DMF
      • CCC
      • Pressure Vessels
    • Publications
    • Brochure
    • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Drug Master Filing
  • The Amended Drug Administration Law

The Amended Drug Administration Law

Friday, 20 September 2019 / Published in Drug Master Filing, News

The Amended Drug Administration Law

On August 26, 2019, the China’s National People’s Congress passed The Amended Drug Administration Law (the Amended DAL) which will go into effect on 01.12.2019. The revised law establishes strict standards and measures in supervision over the whole process of the pharmaceutical industry chain in order to address prominent problems within research and development, manufacturing, sales, management and use of drugs.

The first DAL was released in 1984. This is the first revision since 2001. The new law brings in some changes while consolidating many existing practices, indluding:

– Redefining the scope of counterfeit and inferior drugs
Note: The new definition of counterfeit drugs focuses the definition on active ingredients and claims. Unapproved drugs are not regarded as counterfeit anymore.

– Implementing an improved national Drug Market Authorization Holder (“MAH”) system, including database
Note: foreign pharmaceutical companies are required to appoint a Legal Agent in China, who will need to assume the same regulatory obligations and liability as the foreign MAH.

– Deepening E-pharmacy regulation
Note: the new DAL takes a more lenient approach to online sale of prescription drugs, which must satisfy separate regulations to be issued by the NMPA. High-risk pharmaceutical products are excluded.

– Supporting drug innovation by reforming the drug approval system
Note: certain rules proposed in a pervious draft, which were in favour of innovative pharmaceuticals (including data exclusivity, patent linkage, and the acceptance of foreign clinical trial data for approval) are absent in the Amended DAL.

– Product liability and severe penalties against violation

Tagged under: Drug Administration Law, Drug Market Authorization Holder, drugs, MAH, NMPA, pharmaceutical

What you can read next

Recalls of Medical Device Regulation Updated
Health Food Raw Materials and Functions
From foreign- to China-made medical devices

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Drug Master Filing
      • Health Food
      • Medical Device
    • RoHS
  • Publications
  • Seminars
  • Webinars

Recent Posts

  • Updates on the Medical Device Classification Catalogue in China

    On December 31, 2020, the NMPA announced (No.14...
  • Cisema Partners with Advamed

    Cisema is delighted to announce it is now an as...
  • Guidelines for Sampling Testing on Organic Foods

    On December 4, 2020, the CNCA (Certification an...
  • Draft of Prohibited List and Existing List of Cosmetic Ingredients Announced

    On January 22, 2021, the NIFDC (China National ...
  • Guideline and Standard Update for Medical Devices & IVDs in January and February 2021

    China Regulatory Guidelines Issued / Updated Th...

Archive

Cisema

With nine locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Events
  • News & Information
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2019 Cisema. All rights reserved.

TOP